Undetected chemical impurities and inaccurate substrate quantification compromise drug safety and regulatory compliance. Precise detection ensures product purity and process control in multi-step synthesis.

Insufficient production levels of therapeutic antibodies and vaccines in mammalian and microbial systems. Increasing yield reduces manufacturing costs and improves therapeutic availability.

Low solubility and poor bioavailability limit the therapeutic efficacy of active pharmaceutical ingredients. Overcoming these physical limitations ensures consistent drug delivery and patient safety.